摘要SLE的生物治疗因其特异性针对发病机制的不同环节,已成为SLE治疗的新方向.目前的生物治疗包括B细胞靶向疗法;改变T、B细胞相互作用;抑制相关细胞因子;诱导免疫耐受及补体抑制剂等.仅有小部分生物制剂的临床试验取得预期疗效,其中B细胞靶向疗法较为成功.深入研究SLE不同亚型的作用靶位,优化试验设计,改进评估指标,将研发出更安全有效的药物,并能准确全面评价.

abstractsBiologics selectively target the pathogenesis of SLE at different levels, and have become new therapeutic options for SLE. Current biological treatments include B-cell-targeting therapy, alteration of T and B cell interaction, anti-cytokine therapy, induction of immunotolerance, blockade of complement, etc. To date, only a small part of the biologics have received expected outcomes, and B-cell-targeting therapy seems to be the most promising biological approach. To identify the molecular targets in different SLE subtypes, optimize the design of drug trials, improve disease activity evaluation, will contribute to the development of more effective and safe drugs for, as well as to the complete and accurate evaluation of disease activity of, SLE.